SEC Form 4 · accession 0001140361-15-002401
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Austin Gurney
Officer — See Remarks
Period of report
Jan 20, 2015
Accepted (ET)
Jan 21, 2015 · 9:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Jan 20, 2015 | S | 3,900 | $22.8479 | D | 78,234 | D | |
| Common StockF3 | Jan 20, 2015 | S | 100 | $23.69 | D | 78,134 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 16, 2014.
- F2This transaction was executed in multiple trades in prices ranging from $22.64 to $23.21, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
Remarks
Senior Vice President, Molecular and Cellular Biology